Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8253-8262

  Szarvas, Tibor ^a   Jäger, Tobias ^a   Tötsch, Martin ^b   Dorp, Frank Vom ^a   Kempkensteffen, Carsten ^c   Kovalszky, Ilona ^d   Romics, Imre ^e   Ergün, L Süleyman ^b   Rübben, Herbert ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Experimental Cancer Research   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN; ANGPT1 PROTEIN, HUMAN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; BLADDER TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, TIE-2; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149359823     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0677     Document Type: Article

References (46)

1. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 1991;324:1 -8.
2. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist forTie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
3. Dumont DJ, Gradwohl G, Fong GH, et al. Dominant- negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8: 1897 -909.
4. Papapetropoulos A, Garcia-Cardena G, DenglerTJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79:213-23.
5. Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275: 9102-5.
6. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-8.
7. Ghafar MA, Anastasiadis AG, Olsson LE, et al. Hypoxia and an angiogenic response in the partially obstructed rat bladder. Lab Invest 2002;82:903-9.
8. Sfiligoi C, de Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003; 103:466-74.
9. Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergun S. The expression of angiopoietins and their receptorTie2 in human prostate carcinoma. Anticancer Res 2000;20:5217 -20.
10. Wong MP, Chan SY, Fu KH, et al.The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000; 29:11 -22.
11. Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K. Expression of the angopoietin-1, angopoietin-2,Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004;93:215 -22.
12. Norden-Zfoni A, Desai J, Manola J, et al. Blood- based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:2643-50.
13. Wada H, Nagano H,Yamamoto H, et al. Combinationtherapy of interferon-α and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 2007;18:801 -9.
14. QuentinT, SchlottT, Korabiowska M, et al. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004;24:2745-56.
15. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S. Expression of angiopoietin-1 and-2, and its clinical significancein human bladder cancer. BJU Int 2005;95:660-3.
16. Eble JN, Epstein JI, Sesterhenn I.World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004. p. 89-158.
17. Ohl F, Jung M, Radonic A, Sachs M, Loening SA, Jung K. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol 2006;175: 1915-20.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) methods. Method Methods 2001;25: 402-8.
19. Ergun S, Kilik N, Ziegele rG, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 2000; 5:311 -20.
20. Kilic N, Ergun S. Methods to eveluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis. In: Brooks SA, Schumacher U, editors. Methods in molecular medicine: metastasis research protocols. Cell behavior in vitro and in vivo. Vol. 2. Totowa (NJ): Humana Press; 2001. p. 125 -48.
21. Davidoff MS, SchulzeW, Holstein AF. Combination of alkaline phosphatase anti-alkaline phosphatase (APAAP)- and avidin-biotin-alkaline phosphatase complex (ABAP)-techniques for amplification of immunocytochemical staining of human testicular tissue. Andrologia1991;23:353-6.
22. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for theTIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171 -80.
23. Holash J,Wiegand SJ,Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene1999;18:5356 -62.
24. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407: 242 -8.
25. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1 -10.
26. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003;56: 854-60.
27. Currie MJ, Gunningham SP, Han C, et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001;7: 918-27.
28. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000;82:161 -6.
29. Oliveira-Ferrer L,Tilki D, Ziegeler G, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res 2004;64:8932 -8.
30. Tilki D, Irmak S, Oliveira-Ferrer L, et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene 2006;25: 4965 -74.
31. Chung YC, Hou YC, Chang CN, Hseu TH. Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 2006;94:631 -8.
32. Hou HA, Chou WC, Lin LI, et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008;32:904-12.
33. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N YAcad Sci 2000;902:249-62.
34. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281 -5.
35. Peters KG, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer1998;77:51 -6.
36. Wang J, Wu K, Zhang D, et al. Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastriccancer. Biochem Biophys Res Commun 2005;337:386-93.
37. Saito M, Sato Y,Watanabe J, Kuramoto H, Kaba S, Fukuda T. Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Pathol Int 2007;57: 140-7.
38. Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K. Expression of angiopoietin-1, angio- poietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 2002;62: 340-8.
39. Moon WS, Park HS, Yu KH, et al. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci 2006;21:272 -8.
40. Dales JP, Garcia S, Bonnier P, et al.Tie2/Tek expression in breast carcinoma: correlations of immunohisto-chemical assays and long-term follow-up in a series of 909 patients. IntJ Oncol 2003;22:391 -7.
41. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. SolubleTie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7: 1992-7.
42. Hawighorst T, Skobe M, Streit M, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002;160: 1381 -92.
43. Ergun S,TilkiD, Oliveira-Ferrer L, Schuch G, Kilic N. Significance of vascular stabilization for tumor growth and metastasis. Cancer Lett 2006;238:180-7.
44. Tilki D, Kilic N, Sevinc S, Zywietz F, Stief CG, Ergun S. Zone-specific remodeling of tumor blood vessels affects tumor growth. Cancer 2007;110:2347 -62.
45. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
46. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997;100: 2072-8.